0
LONDON: The development of a novel antidepressant ground to a halt this week when researchers found it did not make patients feel any better than the pills they were already taking.
The drug firms took the hit, with shares tumbling in Targacept, while AstraZeneca wrote off a total of $146.5 million for the drug’s failure.
It was bad news for investors and bad news for patients - and a depressingly familiar tale for drugmakers seeking to develop new treatments for brain illnesses.
Data from Thomson Reuters Pharma shows returns for pharmaceutical companies in the antidepressant market are collapsing - despite widespread use of pills like Prozac - as patents expire and new drugs fail to make it to market.
Some Big Pharma firms are quitting the field altogether. Others are hacking back investment and shedding jobs.
These might seem like prudent decisions in an increasingly expensive and frustrating field. Other diseases such as cancer and diabetes are reckoned to be better areas to be in these days. Yet some scientists say the timing could hardly be worse.
Researchers who study the brain believe they are finally figuring out the basic mechanics of depression and other mental disorders, discoveries that should open the door to far more effective ways to tackle illnesses that can cripple society.
“It’s a great time for brain science, but at the same time a poor time for drug discovery for brain disorders,” says David Nutt, professor of neuropsychopharmacology at Imperial College London. “That’s an amazing paradox which we need to do something about.”
Highest Burden
The numbers say it all.
Major depression affects around 20 per cent of people at some point in their lives. The World Health Organisation predicts that by 2020, depression will rival heart disease as the health disorder with the highest disease burden in the world.
Around a third of all Americans and 40 per cent of all Europeans could be classified as mentally ill, with a European study last year finding that almost 165 million people in the region suffer each year from a brain disorder of some kind.
The study covered more than 100 illnesses from insomnia through depression to schizophrenia. In the developed world, at least, we are popping more pills than ever. One in five adults in the United States is now taking at least one psychiatric drug, according to data from Medco Health Solutions, a pharmacy benefit manager.
But the drugs only work in some of the people some of the time, and there is an urgent need for new, more effective therapies.
“The burden of these diseases is huge, and the costs are enormous -- and it’s only going to get worse with increasing life expectancy,” said Colin Blakemore, professor of Neuroscience at Britain’s Oxford University.
It is a human tragedy that should, in theory, also be a major market opportunity for drugmakers. The problem is that realising the potential gains is proving extremely hard.
“Give a rat cocaine”
Just ask investors who took a punt on TC-5214, the failed antidepressant from AstraZeneca and Targacept. Their rollercoaster ride crashed to a halt on Tuesday.
Back in July 2009 things looked very different as Targacept shares more than doubled after TC-5214 tested extremely well in a mid-stage study. That success could not be replicated in later, larger trials.
AstraZeneca and Targacept are not alone. Last October, Novartis halted work on another antidepressant called agomelatine, resulting in an $87 million charge, adding to other high-profile failures, such as Merck & Co’s aprepitant.
TC-5214 was designed to work in a novel way by modulating nicotine receptors in the brain - a scientific approach that reflects Targacept’s origins inside R.J. Reynolds Tobacco.
The idea seemed good but, compared to testing new medicines in other fields, working out if an antidepressant works is extremely difficult.
The biology of the disease is poorly understood and early tests on animals are not much use either, since mice cannot tell or show scientists what they are feeling.
“Depression is one of the worst areas for animal models,” said Nutt. “It contrasts very strongly with addiction, for example. You give a rat cocaine, it behaves like a human -- it gets hyperactive, it runs around, it likes it, it wants more.
Whereas in depression, the animal models have ... no obvious validity.”
The Placebo effect
Placebo drugs - or sugar pills - typically have a massive impact in lifting depression, underscoring the subtlety of the disease and the suggestibility of patients.
That makes it “very, very hard” to prove that a particular drug is actually working, according to GlaxoSmithKline’s research head Moncef Slaoui.
“You can have depression medicines that in absolute numbers may show a 5 per cent difference versus placebo because there was a placebo response of 50 per cent and a drug response of 55 per cent,” he told Reuters.
